Climb Bio, Inc. (CLYM) - Q3 2025 10-Q Summary
Business Context and Reporting Period
Climb Bio, Inc. is a clinical-stage biotechnology company developing therapeutics for immune-mediated diseases. The reporting period covers the three and nine months ended September 30, 2025. The company is classified as an emerging growth company and a smaller reporting company. Its primary pipeline includes budoprutug (anti-CD19 monoclonal antibody) for indications such as primary membranous nephropathy (pMN), immune thrombocytopenia (ITP), and systemic lupus erythematosus (SLE), and CLYM116 (anti-APRIL monoclonal antibody) for immunoglobulin A nephropathy (IgAN).
Key Financial Metrics
| Metric (in thousands) | Q3 2025 | Q3 2024 | 9M 2025 | 9M 2024 |
|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 |
| Net Loss | $(12,888) | $(8,895) | $(42,335) | $(65,481) |
| Operating Expenses | $14,892 | $11,732 | $48,587 | $71,109 |
| Research & Development (R&D) | $9,073 | $6,240 | $32,975 | $8,377 |
| General & Administrative (G&A) | $5,819 | $5,492 | $15,612 | $11,073 |
| Interest Income | $2,037 | $2,785 | $6,497 | $5,611 |
| Cash & Cash Equivalents | $25,803 | $146,175 | $25,803 | $146,175 |
| Marketable Securities | $150,028 | $125,300 | $150,028 | $125,300 |
| Total Liquidity (Cash + Securities) | $175,831 | $271,475 | $175,831 | $271,475 |
| Accumulated Deficit | $(272,211) | $(221,460) | $(272,211) | $(221,460) |
Note: The company has no product revenue. Liquidity includes cash, cash equivalents, and marketable securities.
Material Changes vs. Prior Period
- Net Loss Improvement (9M): The net loss for the nine months ended September 30, 2025, decreased to $42.3 million from $65.5 million in the prior year. This improvement is primarily due to the absence of a one-time $51.7 million in-process research and development (IPR&D) charge recorded in Q3 2024 related to the acquisition of Tenet Medicines, Inc.
- R&D Expense Increase: R&D expenses increased significantly to $33.0 million for the nine months ended September 30, 2025, compared to $8.4 million in the prior year. This increase is driven by the advancement of clinical trials for budoprutug (pMN, ITP, SLE) and the inclusion of CLYM116 program costs, including a $9.0 million upfront payment to Mabworks in Q1 2025.
- Liquidity Position: Total cash, cash equivalents, and marketable securities decreased to $175.8 million as of September 30, 2025, from $271.5 million as of September 30, 2024. The decrease reflects operating cash burn and net purchases of marketable securities.
- Stock-Based Compensation: Stock-based compensation expense increased to $7.0 million for the nine months ended September 30, 2025, from $3.9 million in the prior year, due to increased headcount and performance-based vesting.
Guidance, Outlook, and Risks
- Cash Runway: Management estimates that current cash, cash equivalents, and marketable securities ($175.8 million) are sufficient to fund operations through 2027.
- Clinical Progress:
- Budoprutug: Initiated Phase 2 trial (PrisMN) in pMN; Phase 1b/2a trial in ITP and Phase 1b trial in SLE are ongoing. A subcutaneous (SC) formulation Phase 1 trial in healthy volunteers is active in Australia.
- CLYM116: Received clearance for a Phase 1 clinical trial in Australia; expects to dose the first subject by year-end 2025.
- Internal Controls: The company disclosed that its disclosure controls and procedures were not effective as of September 30, 2025, due to two unremediated material weaknesses in internal control over financial reporting (lack of sufficient accounting personnel and lack of formal accounting policies/procedures). Remediation efforts are underway.
- Key Risks:
- Dependence on third-party manufacturers and CROs, including single-source suppliers.
- Significant contingent milestone and royalty obligations under license agreements (Acelyrin, CRH, ProBioGen, Mabworks).
- Regulatory uncertainty, including potential impacts of U.S. trade policies and tariffs on Chinese suppliers.
- Need for additional capital to sustain operations beyond 2027.
Investor Verification Checklist
- Remediation of Material Weaknesses: Verify the specific timeline and progress of remediation efforts for the identified internal control weaknesses to ensure future financial reporting reliability.
- Cash Burn Rate: Monitor quarterly operating cash flow to confirm the runway extends through 2027 as projected, given the high R&D spend.
- Clinical Trial Enrollment: Track patient enrollment rates and safety data for the budoprutug Phase 2 (pMN) and Phase 1b/2a (ITP/SLE) trials, as well as the CLYM116 Phase 1 trial.
- License Obligations: Review the specific milestones and potential future cash outflows associated with the Mabworks, Acelyrin, and CRH agreements.
- Supply Chain Exposure: Assess the impact of U.S.-China trade tensions and tariffs on the company's reliance on Chinese manufacturers and suppliers (e.g., WuXi, Mabworks).